Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy

Christian Wolf, Til Menge, Max-Philipp Stenner, Gerd Meyer zu Hörste, Andreas Saleh, Hans-Peter Hartung, Heinz Wiendl, Bernd C. Kieseier
2010 Archives of Neurology  
Objective: To study clinical and paraclinical effects of natalizumab in a patient with chronic inflammatory demyelinating polyneuropathy (CIDP). Design: Case report. Setting: Patient: A patient with highly active CIDP who did not respond to standard therapies. Intervention: Standard therapy then treatment with natalizumab (300 mg). Main Outcome Measures: Clinical disability, magnetic resonance imaging, and saturation of the ␣ 4 integrin on T lymphocytes.
doi:10.1001/archneurol.2010.143 pmid:20625098 fatcat:hknqfpill5aifkk57lvrc5eefm